Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Next Previous
Trial Profile

Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms ORAL Surveillance
  • Sponsors Pfizer

Most Recent Events

  • 03 Jun 2023 Results assessing the benefit/risk profile of tofacitinib by assessing efficacy in pts with RA with and without HxASCVD presented at the 24th Annual Congress of the European League Against Rheumatism
  • 03 Jun 2023 Results of a post-hoc analysis assessing efficacy/safety in the SOC period in patients who discontinued study drug and started SOC treatment presented at the 24th Annual Congress of the European League Against Rheumatism
  • 05 Dec 2022 Results of post hoc analysis, evaluating malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis , published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top